[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638089":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":50,"collaborators":11,"id":53,"slug":11,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexamethasone","ACTIVE_COMPARATOR",null,[13],"Drug: Dexametasone",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Saline (0.9% NaCl)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Dexametasone","dexamethasone 4 mg tid",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Saline (0.9% NaCl)","20 ml saline",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Daša Stupica, MD, PhD","CONTACT","+386 1 522 94 74","dasa.stupica@kclj.si",[36],{"facility":5,"status":37,"city":38,"state":11,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Ljubljana","1000","Slovenia",{"type":42,"coordinates":43},"Point",[44,45],14.50513,46.05108,{"lat":45,"lon":44},[48],{"name":49,"role":32,"phone":33,"phoneExt":11,"email":34},"Daša Stupica",{"type":51,"investigatorFullName":49,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","MD, PhD, assoc. prof.","100638089",false,"NCT07584525","Dexamethasone in Tick-borne Encephalitis","Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical Trial","Inclusion Criteria:\n\n* age 18 years or older and\n* clinical signs and symptoms of meningoencephalitis or meningomyelitis and\n* cerebrospinal pleocytosis and\n* serological confirfmation of tick-borne encephalitis virus infection\n\nExclusion Criteria:\n\n* pregnancy or\n* severe neurological impairment befor tick-borne encephalitis or\n* systemic corticosteroid treatment in the past 30 days or\n* allergy to corticosteroids or\n* immunosuppresive condition or therapy such as HIV with CD4 \\\u003C 200\u002Fml, organ or bone marrow transplant, receiving chemotherapy, radiotherapy or any other immunosuppresive therapy, primary immunodeficiency, hematological maliganncy or\n* ventricular shunt or\n* endoscopically documented peptic gastric ulcer in the past six months or gastrointestinal bleeding with hemoglobin drop ≥ 20 units or\n* uncontrolled diabetes with hyperglicemia or\n* antiviral therapy with rilpivirin",true,"ALL","18 Years",{"count":63,"type":64},200,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","The purpose of this study is to investigate the efficacy of dexamethasone in patients with tick-borne encephalitis.",[70],"Tick-Borne Encephalitis","2026-05-07",{"date":73,"type":74},"2026-05-13","ACTUAL",{"date":76,"type":74},"2024-05-03",{"date":78,"type":64},"2030-09-30",{"name":5,"class":6},1]